Indication
Sickle cell disease with crisis
Sickle cell disease with crisis refers to an acute, severe clinical exacerbation occurring in patients with sickle cell disease, an inherited red blood cell disorder caused by abnormal hemoglobin variants. Read more about Sickle cell disease with crisis
5 drugs 5 manufacturers
Drugs that treat it
Common Sickle cell disease with crisis therapies.
SIKLOS (hydroxyurea)
DROXIA (hydroxyurea)
XROMI (hydroxyurea)
DROXIA (hydroxyurea)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSickle cell disease with crisis refers to an acute, severe clinical exacerbation occurring in patients with sickle cell disease, an inherited red blood cell disorder caused by abnormal hemoglobin variants.
The condition primarily impacts the hematologic and vascular systems, affecting individuals possessing sickling hemoglobinopathies.
Pathophysiologically, deoxygenated sickle hemoglobin polymerizes, deforming erythrocytes into rigid, sickle-shaped cells that occlude microvasculature and provoke tissue ischemia, inflammation, and downstream organ dysfunction.
Defining clinical presentations most commonly encompass acute vaso-occlusive pain episodes affecting the bones, chest, back, and extremities, as well as acute life-threatening emergencies such as acute chest syndrome, splenic sequestration, and aplastic crises.
- nih.gov
Sickle cell disease with crisis refers to an acute, severe clinical exacerbation occurring in patients with sickle cell disease, an inherited red blood cell disorder caused by abnormal hemoglobin variants The condition primarily impacts the hematologic and vascular systems, affecting individuals possessing sickling hemoglobinopathies
- pfizer.com
Sickle cell disease with crisis refers to an acute, severe clinical exacerbation occurring in patients with sickle cell disease, an inherited red blood cell disorder caused by abnormal hemoglobin variants Pathophysiologically, deoxygenated sickle hemoglobin polymerizes, deforming erythrocytes into rigid, sickle-shaped cells that occlude microvasculature and provoke tissue ischemia, inflammation, and downstream organ dysfunction
- nih.gov
The condition primarily impacts the hematologic and vascular systems, affecting individuals possessing sickling hemoglobinopathies
- cdc.gov
Pathophysiologically, deoxygenated sickle hemoglobin polymerizes, deforming erythrocytes into rigid, sickle-shaped cells that occlude microvasculature and provoke tissue ischemia, inflammation, and downstream organ dysfunction
- nih.gov
Pathophysiologically, deoxygenated sickle hemoglobin polymerizes, deforming erythrocytes into rigid, sickle-shaped cells that occlude microvasculature and provoke tissue ischemia, inflammation, and downstream organ dysfunction Defining clinical presentations most commonly encompass acute vaso-occlusive pain episodes affecting the bones, chest, back, and extremities, as well as acute life-threatening emergencies such as acute chest syndrome, splenic sequestration, and aplastic crises
- nih.gov
Defining clinical presentations most commonly encompass acute vaso-occlusive pain episodes affecting the bones, chest, back, and extremities, as well as acute life-threatening emergencies such as acute chest syndrome, splenic sequestration, and aplastic crises
- columbiadoctors.org
Defining clinical presentations most commonly encompass acute vaso-occlusive pain episodes affecting the bones, chest, back, and extremities, as well as acute life-threatening emergencies such as acute chest syndrome, splenic sequestration, and aplastic crises
Personalize your experience
Follow Sickle cell disease with crisis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.